EMIT II Plus Ecstasy Assay

Differentiate MDMA from amphetamines

The EMIT® II Plus Ecstasy Assay is intended for the qualitative and semiquantitative analysis of methylenedioxymethamphetamine (MDMA) and closely related drugs in human urine at a cutoff value of 300 ng/mL or 500 ng/mL. The SAMHSA initial test cutoff level is 500 ng/mL.

Contact Us

Features & Benefits

Methylenedioxymethamphetamine (MDMA), or Ecstasy, is a designer drug. Ecstasy has been called the “love drug” due to the euphoric feelings it produces. This drug of abuse has received notable attention for its use at dance parties called “raves.” Considering the molecular structural similarities between MDMA and its minor metabolite MDA, methamphetamine, and amphetamine, significant cross-reactivity of MDMA and MDA with various amphetamine/methamphetamine immunoassays is not surprising. Immunoassay test results for subjects claiming to have taken MDMA must be viewed cautiously.

The EMIT II Plus Ecstasy Assay provides:

  • Designed to detect MDMA, MDEA, and MDA
  • Excellent precision—all within-lab (total) CVs ≤2.3% or less across the assay range
  • Dual cutoffs available with one assay
  • Ready-to-use liquid reagents, calibrators, and controls
  • 96% correlation with reference method (GC/MS)

 

Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems and AU® Series analyzers.

 

Technical Specifications

 Assay Principle

  Homogeneous Enzyme Multiplied Immonoassay (EMIT)

 Cut-off

  300 ng/mL or 500 ng/mL

 Sample

  Urine  

 Reagent Stability

  Unopened: until expiration date. Onboard instrument: up to 4 weeks

 Calibration Frequency

  As indicated by control results